from Sanofi - Aventis Groupe https://ift.tt/3Npy0tz
via IFTTT
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
0 Comments
Please ,
Do not enter any kind of span link